지노믹트리
Financials
Valuation Metrics
지노믹트리's Market Cap is ₩3177B. At end of 2025 it was ₩6824B. Ranked #617 of 2,436 in KR market (top 25%), #246 of 1,649 on KOSDAQ (top 15%), #69 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 317.70B KRW | KR#617/2,436 Sec#69/234 |
| Revenue | 3.83B KRW | KR#2,363/2,436 Sec#203/234 |
| Net Income | -8.17B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 125.97B KRW | KR#1,587/2,436 Sec#128/234 |
| Net Assets | 123.47B KRW | KR#1,257/2,436 Sec#101/234 |
| Employees | 79 | KR#1,799/2,436 Sec#151/234 |
| Value | ||
| P/B | 2.57x | KR#2,037/2,436 Sec#154/234 |
| P/S | 83.05x | KR#2,380/2,436 Sec#205/234 |
| FCF Yield | -4.07% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -6.62% | KR#1,795/2,436 Sec#134/234 |
| ROA | -6.49% | KR#1,960/2,436 Sec#149/234 |
| Op. Margin | -277.10% | KR#2,357/2,436 Sec#196/234 |
| Revenue Growth | 20.58% | KR#629/2,436 Sec#59/234 |
| Financial Health | ||
| Debt Ratio | 102.02% | KR#331/2,436 Sec#44/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | -12.92B KRW | KR#1,787/2,436 Sec#158/234 |
| Cash | 8.72B KRW | KR#1,749/2,436 Sec#147/234 |
| Current Ratio | 56.88x | KR#5/2,436 Sec#4/234 |
| Performance | ||
| 1Y Return | -9.62% | KR#1,083/2,436 Sec#80/234 |
| 1M Return | 4.24% | KR#1,045/2,436 Sec#92/234 |
| From 52W High | -61.62% | KR#1,858/2,436 Sec#155/234 |
| 1Y MDD | -67.88% | KR#1,845/2,436 Sec#156/234 |
| Trading | ||
| Volume | 155,742 shares | KR#795/2,436 Sec#75/234 |
| Foreign Own. | 2.27% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -328 KRW | KR—/2,436 Sec—/234 |
| BPS | 5,022 KRW | KR#1,434/2,436 Sec#106/234 |
Company Info
Genomictree was established in 2000 as a specialized enterprise for cancer auxiliary diagnosis, listed on KONEX, and then transferred its listing to KOSDAQ in 2019. Headquartered in Yuseong-gu, Daejeon, it possesses DNA methylation biomarker discovery and ultra-sensitive detection technology, developing and commercializing body fluid-based non-invasive early cancer diagnosis products. Its flagship product, EarlyTect-C, received Ministry of Food and Drug Safety approval in 2018 and is sold in domestic hospitals and clinics, with technology transfer completed and product approval applications underway in China.